Dosing Complete and Durable Benefits - TSHA-102 Further Improves With Updates

Research evidence excerpt

Dosing Complete and Durable Benefits - TSHA-102 Further Improves With Updates

June 22, 2026 | 08:40 ET~

Taysha Gene Therapies Biotechnology

Evan David Seigerman Analyst

evan.seigerman@bmo.com (212) 444-4328

TSHA-NSDQ Rating Price: Jun-18 Target Total Rtn

Outperform $6.42 $10.00 56% Malcolm Hoffman, CFA VP Associate

malcolm.hoffman@bmo.com (646) 438-2627

Conor MacKay VP Associate

conor.mackay@bmo.com (347) 988-4235

Legal Entity: BMO Capital Markets Corp.Dosing Complete and Durable Benefits - TSHA-102

Further Improves With Updates

Bottom Line:

Dosing and long-term data updates for TSHA-102 are positive and meaningfully 2YR Price Volume Chart

derisk safety for the therapy going forward. Dosing has completed for TSHA-102 8.00

in the pivotal REVEAL trial without noted serious treatment related adverse events or 7.00

6.00

dose limiting toxicities. While one additional patient in the ASPIRE study will be dosed 5.00

in by the end of July, we view today's update as meaningfully removing safety risks for 4.00 150

3.00TSHA-102. Long-term data further increase confidence in TSHA-102 durability. 100

2.00 50

Key Points 1.00 Dec Jun Dec Jun 0

LHS: Price ($) / RHS: Volume (mm) Source: FactSet

Completion of dosing in REVEAL pivotal trial without serious safety concerns

notably derisks the path forward for future TSHA-102 development. Today's safety

update for the pivotal REVEAL trial increases confidence in the tolerability of TSHA-102

which continues to be dosed without evident treatment related serious adverse events

or dose limiting toxicities (DLTs). While investors were likely growing more comfortable

with TSHA-102's profile over time, completion of dosing marks an important milestone

where we see meaningfully lower risk of more serious HLH reactions which typically